We are applying our deep expertise in the biology of the body’s central mediators and internal pathways to build a biopharmaceutical company with a strong product pipeline, offering new approaches to the treatment of anemia, fibrosis, cancer, and other serious medical conditions.
Our medium and long-term strategies include:
Advancing roxadustat through approval and commercial launch in collaboration with our pharmaceutical partners for treatment of anemia in chronic kidney disease (CKD).
Investigating roxadustat for treatment of anemia in oncology settings, advancing ongoing clinical trials for the treatment of anemia in myelodysplastic syndromes (MDS) and for treatment of anemia in patients undergoing chemotherapy (CIA).
Ongoing Phase 3 clinical studies of pamrevlumab in and locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF).
Maintaining an extensive and multi-layered patent portfolio to protect our technologies and product candidates.
Commitment to China
China is a critical part of FibroGen’s strategy and commitment to deliver groundbreaking therapies for serious diseases. FibroGen’s subsidiary in Beijing, FibroGen China, has manufacturing facilities in the Beijing Technology and Economic Development Agency outside of Beijing and office locations in Beijing, Shanghai, and Cangzhou, Hebei. We are committed to providing accelerated access to transformative medical treatment for patients in China and worked to develop roxadustat for anemia associated with CKD as a domestic Class 1 drug in China, with roxadustat’s December 2018 approval for treatment of anemia in CKD patients on dialysis the first approval for roxadustat, worldwide. Roxadustat is now approved in China for use in treatment of anemia in CKD patients not on dialysis, as well.